Corneodesmosomal Cadherins Are Preferential Targets of Stratum Corneum Trypsin- and Chymotrypsin-like Hyperactivity in Netherton Syndrome
Journal of Investigative Dermatology, ISSN: 0022-202X, Vol: 126, Issue: 7, Page: 1622-1632
2006
- 177Citations
- 75Captures
- 1Mentions
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations177
- Citation Indexes177
- 177
- CrossRef140
- Captures75
- Readers75
- 75
- Mentions1
- References1
- Wikipedia1
Article Description
SPINK5 (serine protease inhibitor Kazal-type 5), encoding the protease inhibitor LEKTI (lympho-epithelial Kazal-type related inhibitor), is the defective gene in Netherton syndrome (NS), a severe inherited keratinizing disorder. We have recently demonstrated epidermal protease hyperactivity in Spink5 −/− mice resulting in desmosomal protein degradation. Herein, we investigated the molecular mechanism underlying the epidermal defect in 15 patients with NS. We demonstrated that, in a majority of patients, desmoglein 1 (Dsg1) and desmocollin 1 (Dsc1) were dramatically reduced in the upper most living layers of the epidermis. These defects were associated with premature degradation of corneodesmosomes. Stratum corneum tryptic enzyme (SCTE)-like and stratum corneum chymotryptic enzyme (SCCE)-like activities were increased, suggesting that these proteases participate in the premature degradation of corneodesmosomal cadherins. SCTE and SCCE expression was extended to the cell layers where Dsg1 and Dsc1 immunostaining was reduced. In contrast, a subset of six patients with normal epidermal protease activity or residual LEKTI expression displayed apparently normal cadherin expression and less severe disease manifestations. This suggests a degree of correlation between cadherin degradation and clinical severity. This work further supports the implication of premature corneodesmosomal cadherin degradation in the pathogenesis of NS and provides evidence for additional factors playing a role in disease expression.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0022202X15329602; http://dx.doi.org/10.1038/sj.jid.5700284; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33745187792&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/16628198; https://linkinghub.elsevier.com/retrieve/pii/S0022202X15329602; http://www.jidonline.org/article/S0022-202X(15)32960-2/abstract; https://secure.jbs.elsevierhealth.com/action/getSharedSiteSession?redirect=http%3A%2F%2Fwww.jidonline.org%2Farticle%2FS0022-202X%2815%2932960-2%2Fabstract&rc=0&code=jid-site; http://acw.elsevier.com/SSOCore?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.jidonline.org%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa-2v5FdT9kc7IARlKxv%2526MAID%253Dndcm7yCQfdCuoIcAtieLwQ%25253D%25253D%2526SERVER%253DWZ6myaEXBLEt1UgI9cIkvA%25253D%25253D%2526ORIGIN%253D92869267%2526RD%253DRD; http://acw.elsevier.com/SSOCore/?return=https%3A%2F%2Fsecure.jbs.elsevierhealth.com%2Faction%2FconsumeSsoCookie%3FredirectUri%3Dhttp%253A%252F%252Fwww.jidonline.org%252Faction%252FconsumeSharedSessionAction%253FJSESSIONID%253Daaa-2v5FdT9kc7IARlKxv%2526MAID%253Dndcm7yCQfdCuoIcAtieLwQ%25253D%25253D%2526SERVER%253DWZ6myaEXBLEt1UgI9cIkvA%25253D%25253D%2526ORIGIN%253D92869267%2526RD%253DRD; https://secure.jbs.elsevierhealth.com/action/consumeSsoCookie?redirectUri=http%3A%2F%2Fwww.jidonline.org%2Faction%2FconsumeSharedSessionAction%3FJSESSIONID%3Daaa-2v5FdT9kc7IARlKxv%26MAID%3Dndcm7yCQfdCuoIcAtieLwQ%253D%253D%26SERVER%3DWZ6myaEXBLEt1UgI9cIkvA%253D%253D%26ORIGIN%3D92869267%26RD%3DRD&acw=&utt=; http://www.nature.com/doifinder/10.1038/sj.jid.5700284; http://linkinghub.elsevier.com/retrieve/pii/S0022202X15329602
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know